Loading
A phase 1/2 trial of JDQ443, TNO155 and Tislelizumab in non-small-cell lung cancer and colorectal cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation is a phase 1/2 interventional study registered as NCT04699188 by Novartis Pharmaceuticals, with 344 participants enrolled, started 2021-02-24 and due to reach its primary completion in 2027-01-25. Interventions recorded: JDQ443, TNO155 and tislelizumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares JDQ443, Advanced Accelerator Applications (Novartis), KRAS G12C-mutant non-small-cell lung cancer, Novartis and the tag pipeline.
Shares KRAS G12C-mutant colorectal cancer, KRAS G12C-mutant non-small-cell lung cancer, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/